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and follow-up care in cases of anaphylaxis.
How common is anaphylaxis?
Anaphylaxis is uncommon but not rare, with new c
rates of between 8.4 and 21 per 100 000 patien
Australian survey of parent-reported allergy andMJA • Volume 185 NumbeABSTRACT
• Anaphylaxis is a serious, rapid-onset, allergic reaction that 
may cause death. Severe anaphylaxis is characterised by life-
threatening upper airway obstruction, bronchospasm and/or 
hypotension.
• Anaphylaxis in children is most often caused by food. 
Bronchospasm is a common symptom, and there is usually a 
background of atopy and asthma.
• Venom- and drug-induced anaphylaxis are more common in 
adults, in whom hypotension is more likely to occur.
• Diagnosis can be difficult, with skin features being absent in 
up to 20% of people. Anaphylaxis must be considered as a 
differential diagnosis for any acute-onset respiratory distress, 
bronchospasm, hypotension or cardiac arrest.
• The cornerstones of initial management are putting the 
patient in the supine position, administering intramuscular 
adrenaline into the lateral thigh, resuscitation with 
intravenous fluid, support of the airway and ventilation, and 
giving supplementary oxygen.
• If the response to initial management is inadequate, 
intravenous infusion of adrenaline should be commenced. 
Use of vasopressors should be considered if hypotension 
persists.
• The patient should be observed for at least 4 hours after 
symptom resolution and referred to an allergist to assist with 
diagnosis, allergen avoidance measures, risk assessment, 
preparation of an action plan and education on the use of self-
injectable adrenaline. Provision of a MedicAlert bracelet 
MJA 2006; 185: 283–289
should also be arranged.
SERIES EDITORS: Andrew Kemp, Raymond Mullins, John Weinerna
sen
chA phylaxis is a severe immediate-type generalised hyper-sitivity reaction affecting multiple organ systems andaracterised at its most severe by bronchospasm, upper
airway angioedema and/or hypotension. It has also been defined
simply as “a serious allergic reaction that is rapid in onset and may
cause death”.1 This review aims to help general practitioners and




found that 1 in 170 school children had suffered at least one
episode of anaphylaxis.5 Another Australian study showed that, in
areas where native Myrmecia ant species are prevalent, 1 in 50
adults have experienced anaphylaxis after stings from native
Myrmecia species (Box 1) or honeybees.6 Deaths from anaphylaxis
are uncommon, estimated to occur at a rate of 1 per 3 million
population per year.7 In areas where sting allergy is common, the
death rate may be higher than this. Hospital-based studies suggest
a death rate in the order of 1 per 100–200 episodes of anaphylaxis
treated in an emergency department.8,9
There is some evidence that the incidence of food allergy and
anaphylaxis — like that of allergic rhinitis and atopic dermatitis —
may be increasing.10-12
What causes anaphylaxis?
Food, insect venoms or medication trigger most cases of anaphylaxis,
with a variable proportion of patients experiencing idiopathic anaph-
ylaxis (in which extensive evaluation fails to identify an underlying
cause) (Box 2). In emergency department studies, food allergy is the
commonest cause in children — responsible for about 80% of
anaphylactic reactions in which the cause has been identified13 —
whereas, in adults, foods are implicated in only 20%–30% of cases.8,9
This difference is reflected in mortality statistics: the median ages for
lethal reactions to foods and to insect venoms or medications are 22–
24 years and 55–67 years, respectively.14
Summation anaphylaxis
Cofactors are sometimes required before an allergen will provoke a
reaction. Factors associated with increased risk of anaphylaxis
include intercurrent infection, concomitant medication/foods (par-
ticularly α-blockers, β-blockers, angiotensin-converting enzyme
[ACE] inhibitors, non-steroidal anti-inflammatory drugs
[NSAIDS], alcohol or spicy food), high ambient temperatures and
exercise. So-called “summation anaphylaxis” may explain intermit-
tent anaphylaxis despite frequent allergen exposure, and may
account for some cases in which a cause has not been estab-
lished.15 One of the most common cofactors, predominantly
affecting young adults, is physical exercise. Some experience
symptoms with exercise alone; others do so only if allergenic foods
(most commonly wheat, celery, seafood, nuts, fruit or vegetables)
are ingested within a few hours prior to exercise.
What happens in anaphylaxis?
Mast cell leukocyte cytokine cascade
Mast cell activation results in the release of many mediators that
include histamine, leukotrienes, tumour necrosis factor and vari-
ous cytokines. The large numbers of mediators provide redun-
dancy and positive feedback mechanisms whereby other effector
cells are recruited to release more mediators, perpetuating the
allergic response. This amplification and perpetuation, which has
been referred to as a “mast cell leukocyte cytokine cascade”,16
underscores the importance of physiological antagonism with
adrenaline and fluid resuscitation, rather than antagonism of a
single mediator such as histamine.r 5 • 4 September 2006 283
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Anaphylactic mediators cause vasodilation,
fluid extravasation, smooth muscle contrac-
tion and increased mucosal secretions.
Death may occur from hypoxaemia (due to
upper airway angioedema, bronchospasm
and mucus plugging) and/or shock (due to
massive vasodilation, fluid shift into the
extravascular space and depressed myocar-
dial function).17 While compensatory tachy-
cardia in response to hypotension is
considered a characteristic feature, sudden
bradycardia with cardiovascular collapse
and cardiac arrest may occur before any skin
features become apparent.18 The cause of
this phenomenon is unclear, but it is an
important clinical feature to recognise in
order to avoid making an initial misdiagno-
sis of a “panic attack” or “vasovagal reaction”
in cases where dyspnoea, nausea, anxiety,




The clinical features of anaphylaxis are sum-
marised in Box 3. Skin features are almost
universal if reactions are closely observed,
but erythema (and even angioedema) may
be subtle and missed if not carefully looked
for (Box 4). Respiratory symptoms are more
common in children, whereas cardiovascu-
lar and cutaneous symptoms dominate in
adults.13 In part, this may be related to the
higher frequency of atopy, asthma and food
allergy in children.13 Pre-existing lung dis-
ease is associated with an increased fre-
quency of respiratory compromise from any
cause,6,9 and poorly controlled asthma
appears to be the main risk factor for child-
hood death due to food allergy.19
Confusion, collapse, unconsciousness and
incontinence are strongly associated with
the presence of hypotension and hypoxia. In
adults, the occurrence of dyspnoea, profuse
sweating, nausea, vomiting and abdominal
pain are also significant, as they correlate
with the presence of hypotension.9
Does definition matter?
Lack of a universally accepted definition and severity grading
system for anaphylaxis, and lack of a reliable biomarker to confirm
the diagnosis, has not only hampered research but has also
resulted in failure to diagnose and treat anaphylaxis in a consistent
and timely manner. A simple definition has been applied by the
Australasian Society of Clinical Immunology and Allergy (ASCIA):
Anaphylaxis is a rapidly evolving generalised multi-system
allergic reaction characterised by one or more symptoms or
signs of respiratory and/or cardiovascu-
lar involvement and involvement of
other systems such as the skin and/or
the gastrointestinal tract.20
This definition will exclude some atypical
yet still life-threatening reactions, and more
recently, an international consensus working
definition has been proposed to address
these issues.1 However, no definition has yet
been subject to prospective validation. Thus
it may be important at times to initiate
treatment for a suspected case of anaphy-
laxis with cardiovascular or respiratory com-
promise, even if consensus diagnostic
criteria have not been met.
Differential diagnosis
The many possible causes of hypotension
should be considered in patients suffering
shock. Rashes and angioedema should not
be assumed to be the result of anaphylaxis.
A range of conditions may be confused with




Acute management of anaphylaxis (Box 6,
Box 7) includes the following:
• Place the patient in the supine position
(or left lateral position for vomiting
patients);
• Give intramuscular adrenaline;
• Resuscitate with intravenous saline (20mL/
kg body weight, repeated up to a total of
50mL/kg over the first half hour);
• Support the airway and ventilation; and
• Give supplementary oxygen.17
Intramuscular 1 : 1000 (1 mg/mL) adrena-
line at a dose of 0.01 mg/kg (0.01 mL/kg)
body weight up to a maximum dose of
0.5 mg (0.5 mL) injected into the lateral
thigh (vastus lateralis) has the advantage that
it can be given without delay, is absorbed
more reliably than injections into other loca-
tions or subcutaneously,21,22 is anecdotally
effective in most cases when given early, and
avoids the potentially lethal effects of large
intravenous bolus injections.14 The appro-
priate dose of EpiPen (CSL Limited, Mel-
bourne, VIC) (Box 8) can be used instead, if available. The
intramuscular dose can be repeated after 3–5 minutes if required.
Intravenous adrenaline
If resuscitation using intramuscular adrenaline and volume expan-
sion with intravenous saline is ineffective, an infusion of intrave-
nous adrenaline may be required, but this should be done only by
experienced hands. Intravenous boluses of adrenaline are poten-
1 Jack jumper ant (Myrmecia 
pilosula)
The jack jumper ant is endemic to Australia 
and a major cause of anaphylaxis in regional 
south-eastern Australia. Body length (from 
top of head to tip of abdomen) is 
approximately 10–12 mm. ◆
2 Causes of anaphylaxis
Common
• Insect stings: most commonly honeybee, 
Australian native ants, wasps
• Foods: most commonly peanuts, tree 
nuts, egg, seafood, cows milk, dairy 
products, seeds
• Medications: most commonly antibiotics, 
non-steroidal anti-inflammatory drugs
• Unidentified (no cause found)
Less common
• Physical triggers (eg, exercise, cold)




• Hormonal changes: breastfeeding, 
menstrual factors
• Dialysis membranes (haemodialysis-
associated anaphylaxis)
• Hydatid cyst rupture
• Aeroallergens: domestic/laboratory 
animals, pollen
• Food additives: monosodium glutamate, 
metabisulfite, preservatives, colours, 
natural food chemicals
• Topical medications (eg, antiseptics) ◆284 MJA • Volume 185 Number 5 • 4 September 2006
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imminent. Controlled intravenous infusions of adrenaline were
shown to be safe and effective in one prospective Australian
study.18 An infusion protocol derived from this study has been
published elsewhere.17
Management of persistent airway tract obstruction and/or 
hypotension
If the patient is still unresponsive after the treatments outlined
above, there are several further options:
• Persistent bronchospasm may respond to treatment with addi-
tional bronchodilators. If intubation is required, continuous puffs
of salbutamol through an aerosol port directly into the ventilation
circuit may help to “break” severe bronchospasm.
• Persistent stridor may respond to continuous nebulised adrena-
line (5 mg in 5 mL [ie, five 1 mg ampoules]) in addition to
parenteral adrenaline. Surgical airway intervention (cricothyro-
tomy) may be required.
• Persistent hypotension may be due to either profound vasodila-
tion or cardiac failure. Anecdotally, vasodilation may respond to
vasopressors such as metaraminol or vasopressin.26-28 In patients
who have pre-existing heart failure or are taking β-blockers, a
phosphodiesterase inhibitor such as glucagon may be tried.29,30
Ancillary medications
Medications such as antihistamines, H2 receptor antagonists,
corticosteroids and antileukotrienes have no proven impact on the
immediate and dangerous effects of anaphylaxis, although they
may ameliorate mild allergic reactions confined to the skin. The
only registered antihistamine for parenteral use in Australia,
promethazine, can worsen vasodilation and hypotension, and its
use is not advised.17,31 Until human research clarifies the potential
risks and benefits of antihistamines, it is prudent to restrict
antihistamine use to oral, selective, non-drowsiness-inducing anti-
histamines, with or without oral or injectable corticosteroids, for
the symptomatic relief of mild skin symptoms. Based on their use
in treating asthma, corticosteroids are commonly given to reduce
the risk of biphasic anaphylaxis (see below), although there is
currently no evidence to support their effectiveness for this
purpose.
Investigation
Anaphylaxis remains a largely clinical diagnosis. Serum mast cell
tryptase concentration can be determined, but this is an insensitive
biomarker for anaphylaxis, although serial measurements (eg, on
arrival, 1 hour later and before discharge) may improve sensitivity
and specificity.32 An elevated tryptase level may be a useful clue
when the diagnosis is uncertain, but a normal result does not
exclude anaphylaxis.
Observation
The time course of anaphylaxis can be classified as “uniphasic”,
“protracted” or “biphasic”.33 Although most reactions respond
rapidly to treatment and do not recur (uniphasic reactions), an
observation period is recommended. This is because, in some
patients, symptoms may fail to improve or may worsen as the
effect of adrenaline wears off (protracted anaphylaxis) or may
return after early resolution (biphasic reaction). No clinical
feature consistently identifies patients at risk of a biphasic
reaction. Expert consensus is that a reasonable length of observa-
tion after symptom resolution is 4–6 hours in most patients, with
more prolonged observation in those with severe or refractory
symptoms and those with reactive airway disease, as most













• Pelvic pain (described as 




• Vascular headache (typically 
described as “throbbing”)
•Dizziness*





•Dysphagia and stridor 
due to upper airway 
angioedema†











• ECG changes 




* These features are associated with 
hypotension.9
† These features are associated with 
hypoxia.9 ◆
4 Facial erythema and oedema, seconds before the 
onset of severe anaphylaxis with hypotension
Flushing and oedema can be transient, subtle and easily 
overlooked. Sometimes the only clue may be “normal” (warm, 
well perfused) skin in the setting of circulatory collapse, when pallor 
and poor perfusion would be the norm. In cases of acute-onset 
bronchospasm or hypotension, look carefully for these features 
and ask relatives or friends if they have noticed any changes. 
(Reproduced with permission from the patient.) ◆MJA • Volume 185 Number 5 • 4 September 2006 285
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these patients.1
Poorly controlled asthma is the main risk
factor for death in children. Age over 35 years
and previous severe reactions are the main risk
factors for hypotension and death in adults.
After the acute episode
Before examining the surrounding circum-
stances to define a cause for the patient’s symp-
toms (Box 2), it is important to first determine
whether anaphylaxis occurred by carefully
reviewing the available documentation. Short-
lived bouts of urticaria and/or angioedema last-
ing less than 12 hours should prompt suspicion
of an allergic cause, although on their own they
do not satisfy a definition of anaphylaxis. As
typical cutaneous features may be absent in up
to 20% of cases, anaphylaxis should be consid-
ered in the differential diagnosis of any episode
of severe, acute-onset respiratory distress, bron-
chospasm or cardiovascular collapse (Box 9).
Details of exposure to potential triggers,
including occupational allergens (eg, latex) and
cofactors, in the preceding 8 hours should be
recorded while memory of the event is fresh.
Almost all anaphylactic reactions to insect ven-
oms or to food or medication occur within 1 and
6 hours, respectively.2
Medical practitioners should record the pres-
ence of known food or drug hypersensitivity and
consider the possibility of accidental exposure.
Ask patients about symptoms of contact urticaria
(eg, during food preparation) or itching in the
mouth and throat after eating certain foods (oral
allergy syndrome). The latter indicates an allergy
to structurally similar proteins in pollen and in
some fruit and vegetables.2 If an insect sting has
occurred, factors that may help identify the
cause are the insect’s appearance, the presence of
a stinger left in the skin (pathognomonic for
honeybee sting) and the location where the sting
occurred (stings by jack jumper ants or bulldog
ants are more common in bushland).
Investigation
In-vitro testing for allergen-specific IgE (using a
radioallergosorbent test [RAST] or ImmunoCAP
[Phadia AB, Uppsala, Sweden]) is a useful initial
screening test for a variety of allergens. In-vitro
testing has limitations because the test lacks
sensitivity and is limited by the range of aller-
gens available and the ability to claim Medicare
rebates for only four allergens at a time.
Skin prick testing, to assess sensitisation to
food, and skin prick testing (or sometimes
intradermal testing), to assess allergy to medi-
cations or insect venom, are more sensitive
than in-vitro testing. As these carry a small risk
of inducing anaphylaxis, they should only be
carried out in an environment in which
resources for treating anaphylaxis are available.
Measurement of total IgE and in-vitro testing
using food mixes frequently provide misleading
or irrelevant results and should not be
requested.
There is currently no test to confirm tick bite
allergy. Skin testing for jack jumper ant allergy
is not yet available outside the Royal Hobart
Hospital in Tasmania, although an in-vitro test
is available from SouthPath Laboratories in
South Australia (this detects only 80% of cases,
and, while the subject of ongoing research,
there is no validated test to detect allergy to
related ant species).
Some drug reactions (eg, to NSAIDS, radio-
graphic contrast agents) are independent of IgE,
and there are numerous difficulties in assessing
some cases of antibiotic allergy. To establish a
diagnosis in cases in which the causative agent
is in doubt, challenge testing under controlled
conditions may sometimes be required,
although a negative challenge test does not
always exclude the diagnosis.
There is no scientific validity for “alternative”
therapies such as cytotoxic or Vega testing, hair
analysis and kinesiology, and their use should
be discouraged.34
Long-term management
Anaphylaxis to insect stings can be prevented
with venom immunotherapy,23 which reduces
the risk of anaphylaxis from repeated stings
and is associated with an improved quality of
life compared with carrying an EpiPen alone.24
Attempts to modify the severity of food allergy
using similar techniques have thus far failed,
although novel methods of inducing tolerance
hold some promise for the future.35
For most patients, anaphylaxis is a disorder
for which the risk of relapse is chronic but the
event itself is unpredictable.2 The mainstays of
long-term management of anaphylaxis
include:
• Specialist assessment.
• Identification and avoidance of triggers and
cofactors, if possible. Common triggers of
anaphylaxis include food, stinging insects and
medication. Exercise, alcohol consumption
and taking NSAIDS are common cofactors.
• Avoidance of medications that may compli-
cate management.
• Training patients to recognise early warn-
ing symptoms and to carry self-injectable
adrenaline (EpiPen) (after being trained in its
use).
• Provision of a written anaphylaxis action
plan.







• Acquired or hereditary C1 esterase 
inhibitor deficiency
Conditions mimicking upper airway 
oedema
• Dystonic reactions mimicking 
symptoms of a swollen tongue 
after taking metoclopramide, 
prochlorperazine or antihistamines
• Acute oesophageal reflux (sudden 
onset of painful throat “swelling”)
Flushing syndromes
• Peptide-secreting tumours (eg, 
carcinoid syndrome, VIPomas†)
• Alcohol-related
• Medullary carcinoma of thyroid




Other causes of collapse
• Vasovagal episodes
• Systemic inflammatory response 
syndrome







• Vocal cord dysfunction
Miscellaneous




ACE = angiotensin-converting enzyme. 
* Isolated angioedema lacks any other 
organ or systemic features and thus by 
definition is not anaphylaxis. 
† Neuroendocrine tumours that secrete 
vasoactive intestinal polypeptide. ‡ “Red 
man syndrome” is flushing and erythema 
associated with infusion of vancomycin (or 
occasionally other antibiotics). It is thought 
to be due to histamine release, and may 
be related to dose or infusion rate. 
§ Although included here to prompt a 
consideration of this underlying disease, 
systemic mastocytosis is, strictly speaking, 
a cause of anaphylaxis. ◆286 MJA • Volume 185 Number 5 • 4 September 2006
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and entry of an allergy alert into hospital or health care network
clinical information systems.
A number of resources for patients and health care professionals,
including guidelines for dealing with anaphylaxis in specific
settings such as schools and childcare centres, prescribing guide-
lines and written action plans, are available on the ASCIA website
(http://www.allergy.org.au/anaphylaxis). The EpiPen doses com-
monly recommended by specialist bodies (such as ASCIA) differ
from those in the package insert. ASCIA recommends prescribing
EpiPen Junior (0.15 mg) for patients weighing 10–20 kg and
EpiPen (0.3 mg) for patients weighing over 20 kg.
Wearing a MedicAlert bracelet (Australia MedicAlert Founda-
tion, Adelaide, SA) may give attending medical or paramedical
personnel access to additional information about known allergies,
reduce the risk of administration of allergenic medication, and
facilitate earlier recognition and treatment of anaphylaxis.
Despite their widespread clinical use, medications such as
antihistamines and corticosteroids have no proven efficacy in
preventing or treating anything other than mild cutaneous allergic
symptoms. Furthermore, the cost of maintaining or using these
medications in people with anaphylaxis due to other causes needs
to be balanced against the cost of purchasing an additional EpiPen.
Large doses of adrenaline may be required to treat hypotensive
anaphylaxis,18 so Australians living in remote areas may need
additional supplies beyond the single EpiPen unit subsidised by
the current Pharmaceutical Benefits Scheme for individuals over
17 years of age. Even if an initial EpiPen injection has been
effective, patients should seek emergency medical care without
delay. Patients who live or work in remote areas should consider
having access to means of summoning emergency assistance, such
as a mobile telephone or, in some cases, an emergency satellite
beacon.
7 Evidence-based practice tips*
• Recommended acute management of a patient with anaphylaxis 
is to place the patient in a supine position and give adrenaline and 
intravenous volume resuscitation (Level IV).1
• Intramuscular injection into the lateral thigh (vastus lateralis) is 
preferred to injections into arm or deltoid muscles or 
subcutaneously, because of better absorption (Level III-1).21,22
• A controlled intravenous infusion of adrenaline is a safe and 
effective management for anaphylaxis (Level III-3).18
• A reasonable length of observation after symptom resolution is 
4–6 hours in most patients, with more prolonged observation 
recommended in patients with severe or refractory symptoms 
(Level IV).1
• Venom immunotherapy prevents anaphylaxis to insect stings and 
significantly improves quality of life compared with carrying 
injectable adrenaline (EpiPen) alone (Level II).23,24
* Based on National Health and Medical Research Council levels of 
evidence.25 ◆
6 Emergency management of anaphylaxis
IM = intramuscular. IV = intravenous. Adapted with permission from: Brown SGA. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas 2006; 18:
155-169.17  ◆
EMERGENCY MANAGEMENT OF ANAPHYLAXIS
Call for assistance
Give adrenaline IM (lateral thigh) 0.01 mg/kg (maximum dose 0.5 mg)
Set up IV access
Lay patient flat (elevate legs if tolerated)
Give high flow oxygen + airway/ventilation support if needed
IF HYPOTENSIVE, ALSO:
Set up additional wide-bore IV access (ie, 14G or 16G in adults) for normal saline infusion
Give IV normal saline bolus 20 mL/kg over 1–2 min under pressure
2
Start an IV adrenaline infusion, as per hospital guidelines/protocol
OR
Repeat IM adrenaline injection every 3–5 min, as needed
1  Stop administration of causative agent (if relevant), assess reaction severity and treat accordingly
If there is inadequate response, an immediate life-threatening situation, or deterioration:MJA • Volume 185 Number 5 • 4 September 2006 287
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Specialist evaluation is recommended after a diagnosis of possi-
ble anaphylaxis — to identify or confirm the cause, to educate
regarding appropriate avoidance strategies, to help in drafting an
emergency action plan and to advise whether immunotherapy is
appropriate. There is anecdotal evidence that certain medications
used to manage blood pressure and heart problems (α-blockers,
β-blockers and ACE inhibitors) may worsen anaphylaxis or
interfere with the action of adrenaline administered in an
emergency. However, this poorly defined risk needs to be
balanced against the proven benefits that these medications
provide. For patients taking cardiac medications, the relative
risks and benefits of their use should be considered in consulta-
tion with an allergist and/or other specialists.
Despite the frightening nature of anaphylactic episodes, com-
pliance with advice to avoid known triggers and to carry and use
injectable adrenaline is nowhere near 100%.2 Denial and “acting
out” by teenagers is also common, and peer pressure or bullying
at school may prompt some patients to take unnecessary risks.
Review from time to time or after further episodes offers an
opportunity to re-educate patients on the use of EpiPen and to
ensure that the device is renewed at appropriate intervals.
Psychological morbidity and negative impact on quality of life are
not uncommon in patients and their caregivers, and some require
emotional support and counselling as well as medical advice.
9 Case scenario*
A 63-year-old man experienced sudden cardiovascular collapse at 
02:00 in his home. This had been preceded by urticaria and a desire 
to open his bowels. He was hypotensive, but responded to 
treatment by paramedics (two 0.5 mg doses of intramuscular 
adrenaline into the lateral thigh, 5 minutes apart, and rapid 
intravenous infusion of 2 L saline).
Earlier that evening, he had eaten a buffet meal consisting of bread, 
various meats, vegetables, salads, sauces and alcohol, had been 
dancing, and had taken ibuprofen for a headache before retiring to 
bed at midnight. Concurrent medical problems included ischaemic 
heart disease (treated daily with a β-blocker).
The patient was observed in the emergency department for 24 
hours. There were no ECG changes, and there was no melaena or 
rise in troponin level. His serum mast cell tryptase level was later 
reported as 25 μg/L on arrival in the emergency department, falling 
to 15 μg/L at the time of discharge, confirming the diagnosis of 
anaphylaxis.
Management
Allergy testing showed no convincing evidence of food 
hypersensitivity. The diagnostic possibilities of food or drug 
hypersensitivity were considered, with or without involvement of 
cofactors like alcohol, exercise and consumption of an NSAID.
The long interval between exercise and onset of a reaction was 
considered to make exercise an unlikely cofactor. In-hospital graded 
challenge with ibuprofen was negative. A provisional diagnosis of 
idiopathic anaphylaxis was made, although it was not possible to 
completely exclude an unidentified food allergen or summation 
anaphylaxis (eg, unidentified food allergen ±NSAID ±exercise).
The initial difficulties in resuscitation, requiring two doses of 
adrenaline and fluid resuscitation, were considered partially 
attributable to β-blockade. After discussions with his cardiologist, it 
was concluded that the patient could be safely given an alternative 
cardiac medication and that the risk from untreated anaphylaxis 
outweighed the theoretical risk of adrenaline triggering myocardial 
ischaemia.
The patient was advised to carry and use injectable adrenaline 
(EpiPen) in an emergency, and to document the circumstances in any 
future reactions to assist in identifying an avoidable trigger.
ECG = electrocardiogram. NSAID = non-steroidal anti-inflammatory drug. 
* This is a fictional case scenario based on similar real-life cases. ◆
8 EpiPen administration
The grey “locking” cap is first removed. This enables the device, so 
that, when the opposite (black) end is pressed against the lateral 
thigh, the needle is activated and the adrenaline injected.
The correct point of injection is the outer thigh. The needle is 
designed to penetrate thick clothing. A common error is to press the 
grey end against the thigh while pressing the thumb onto the black 
tip, thus injecting the adrenaline into the thumb. To prevent this, we 
advise patients to always grip the device as shown. ◆288 MJA • Volume 185 Number 5 • 4 September 2006
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Fact or fiction — true or false?
1. Adrenaline should not be given to patients with anaphylaxis who 
are pregnant, elderly, or taking α-blockers or β-blockers (T/F)
2. Intravenous bolus injection of adrenaline is safe (T/F)
3. Even in an emergency department (where intravenous infusion is 
an option), intramuscular injection of adrenaline is an appropriate 
first-line treatment for anaphylaxis (T/F)
1. False. Although some caution with the dose may be wise, the overriding 
concern is that hypoxia or poor tissue perfusion will lead to ischaemia of 
critical organs (or harm the fetus).
2. False. This is how lethal errors are made. Even the “correct” dose can cause 
severe side effects. A controlled infusion is much safer, better tolerated and 
more efficacious, as a sustained therapeutic concentration is obtained.
3. True. Adrenaline given into the lateral thigh can result in useful serum levels 
of adrenaline within 3–5 minutes — the time that may be required to get 
intravenous access and start an infusion. In many cases, intramuscular 
adrenaline is effective on its own. ◆MJA • Volume 185 Number 5 • 4 September 2006 289
